Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/8/2017
SIETES contiene 91969 citas

 
 
 1 a 20 de 7402 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Varga S, Alcusky M, Keith SW, Hegarty SE, Del Canale S, Lombardi M, Maio V. Hospitalization rates during potentially inappropriate medication use in a large population-based cohort of older adults. Br J Clin Pharmacol 2017:4 de agosto. [Ref.ID 102012]
2. Cita con resumen
Ma GK, Brensinger CM, Wu Q, Lewis JD. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med 2017;167:152-8. [Ref.ID 101991]
3. Cita con resumen
Waade RB, Molden E, Martinsen MI, Hermann M, Ranhoff AH. Psychotropics and weak opioid analgesics in plasma samples of older hip fracture patients – Detection frequencies and consistency with drug records. Br J Clin Pharmacol 2017;83:1397-404. [Ref.ID 101985]
4. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
6. Cita con resumen
Rojas-Velandia C, Ruiz-Garzón J, Moscoso-Alcina J-C, Vallejos-Narváez A, Castro-Canoa J, Bustos-Martínez Y, Flórez-Cutiva M, Contreras-Muñoz M, Gómez-Gil JC, Calderón-Ospina C-A. Characterization of adverse drug reactions causing admission to an intensive care unit. Br J Clin Pharmacol 2017;83:1134-40. [Ref.ID 101974]
7. Cita con resumen
Nair NP, Chalmers L, Bereznicki BJ, Curtain C, Peterson GM, Connolly M, Bereznicki LR. Adverse drug reaction-related hospitalizations in elderly Australians: a prospective cross-sectional study in two Tasmanian hospitals. Drug Saf 2017;40:597-606. [Ref.ID 101969]
8. Cita con resumen
Gedeborg R, Svennblad B, Holm L, Sjögren H, Bardage C, Personne M, Sjöberg G, Feltelius N, Zethelius B. Increased availability of paracetamol in Sweden and incidence of paracetamol poisoning: using laboratory data to increase validity of a population-based registry study. Pharmacoepidemiol Drug Saf 2017;26:518-27. [Ref.ID 101958]
9. Cita con resumen
Wei L, Ratnayake L, Phillips G, McGuigan CC, Morant SV, Flynn RW, Mackenzie IS, MacDonald TM. Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study. Br J Clin Pharmacol 2017;83:1298-308. [Ref.ID 101942]
10. Cita con resumen
Sevilla-Sánchez D, Molist-Brunet N, Amblàs-Novellas J, Roura-Poch P, Espaulella-Panicot J, Codina-Jané C. Adverse drug events in patients with advanced chronic conditions who have a prognosis of limited life expectancy at hospital admission. Eur J Clin Pharmacol 2017;73:79-89. [Ref.ID 101938]
11. Cita con resumen
Walter SR, Day RO, Gallego B, Westbrook JI. The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. Br J Clin Pharmacol 2017;83:416-26. [Ref.ID 101933]
12. Cita con resumen
Ramírez E, Medrano-Casique N, Tong HY, Bellón T, Cabañas R, Fiandor A, González-Ramos J, Herranz P, Trigo E, Muñoz M, Borobia AM, Carcas AJ, Frías J. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. Br J Clin Pharmacol 2017;83:400-15. [Ref.ID 101932]
13. Cita con resumen
Kua KP, Lee SWH. Systematic review and meta-analysis of clinical outcomes of early caffeine therapy in preterm neonates. Br J Clin Pharmacol 2017;83:180-91. [Ref.ID 101930]
14. Cita con resumen
Thomas K. Celgene to pay $280 Million to settle fraud suit over cancer drugs. N Y Times (Print) 2017:1. [Ref.ID 101924]
15. Cita con resumen
Anónimo. Se recomienda no iniciar nuevos tratamientos con ?Monoferro® (hierro-isomaltósido) debido al riesgo de reacciones graves de hipersensibilidad. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:1-2. [Ref.ID 101915]
16. Cita con resumen
Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol 2017;73:759-70. [Ref.ID 101675]
17. Cita con resumen
Anónimo. Sélexipag et hypertension artérielle pulmonaire. Prescrire 2017;37:337. [Ref.ID 101648]
18. Cita con resumen
Anónimo. Guanfacine et déficit de l'attention avec hyperactivité. Prescrire 2017;37:329-32. [Ref.ID 101647]
19. Cita con resumen
Anónimo. Ramucirumab et cancer bronchique en 2e ligne. Prescrire 2017;37:337. [Ref.ID 101646]
20. Cita con resumen
Anónimo. Ibrutinib et leucémie lymphoïde chronique en première ligne. Prescrire 2017;37:335-6. [Ref.ID 101645]
Seleccionar todas
 
 1 a 20 de 7402 siguiente >>